MedTrace Logo

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

NCT05876806 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-11-30

No results posted yet for this study

Summary

This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with solid tumors with BRAF V600E mutation or clinically actionable BRAF gene alterations.

Conditions

Interventions

DRUG

Dabrafenib

Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis

DRUG

Trametinib

Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.

Sponsors & Collaborators

  • Se Jun Park

    lead OTHER

Principal Investigators

  • Se Jun Park, MD, PhD · The Catholic University of Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05876806 on ClinicalTrials.gov